On September 3, Yunnan Baiyao Group Co.,Ltd. (000538) announced that it held an investor research meeting on September 1, 2025, with a total of 125 institutional and individual investors participating. Chairman Zhang Wenxue stated that despite industry pressures, the company achieved revenue of 21.257 billion yuan, representing a year-on-year increase of 3.92%. Net profit attributable to shareholders reached 3.633 billion yuan, up 13.93% year-on-year, setting a historical record. Basic earnings per share stood at 2.04 yuan, increasing 13.97% compared to the same period last year. Meanwhile, industrial revenue's share of total revenue rose to 40.01%, with growth reaching 11.13%. The company will strengthen its strategic transformation capabilities, focus on efficient execution to drive high-quality development, and continuously advance innovation management to optimize corporate governance standards. Following the acquisition of Juyaotang, the company will integrate its business and resources to enhance synergy efficiency across the traditional Chinese medicine supply chain. Yunnan Baiyao aerosol achieved sales revenue exceeding 1.453 billion yuan in the first half, growing more than 20.9% year-on-year. The Health Products Business Group realized operating revenue of 3.442 billion yuan in the first half, up 9.46% year-on-year. In the second half, the company will continue to increase R&D investment and market expansion to maintain healthy and sustainable development. For the interim period of 2025, Yunnan Baiyao Group Co.,Ltd. achieved revenue of 21.257 billion yuan and net profit attributable to shareholders of 3.633 billion yuan.
Comments